HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Pathophysiology, diagnosis, and treatment of paroxysmal nocturnal hemoglobinuria: a review.

Abstract
Paroxysmal nocturnal hemoglobinuria (PNH) is an acquired disorder of the hematopoietic stem cell that makes blood cells more sensitive to the action of complement. Patients experience intravascular hemolysis, smooth muscle dystonia, renal failure, arterial and pulmonary hypertension, recurrent infectious diseases and an increased risk of notably dreadful thrombotic complications. The diagnosis is made by flow cytometry. Efforts have been recently performed to improve the sensitivity and the standardization of this technique. PNH is frequently associated with aplastic anemia or low-risk myelodysplasia and may be asymptomatic. Management of the classical form of PNH has been dramatically revolutionized by the development of eculizumab, which brings benefits in terms of hemolysis, quality of life, renal function, thrombotic risk, and life expectancy. Prophylaxis and treatment of arterial and venous thrombosis currently remain a challenge in PNH.
AuthorsBérangère Devalet, François Mullier, Bernard Chatelain, Jean-Michel Dogné, Christian Chatelain
JournalEuropean journal of haematology (Eur J Haematol) Vol. 95 Issue 3 Pg. 190-8 (Sep 2015) ISSN: 1600-0609 [Electronic] England
PMID25753400 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)
Copyright© 2015 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
Topics
  • Hemoglobinuria, Paroxysmal (diagnosis, etiology, therapy)
  • Humans

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: